The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.
There is no clear indication regarding the treatment of patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200. Treatment of eyes with low visual acuity could lead to a waste of resources, without any functional and social improvements. Aim of the present study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
20
1.25 mg intravitreal bevacizumab
IRCCS San Raffaele
Milan, MI, Italy
change in best-corrected visual acuity
change in best-corrected visual acuity at the end of the follow-up
Time frame: 6 months
change in central macular thickness
change in central macular thickness on OCT
Time frame: 6 months
NEI VFQ-25 scores
change in NEI VFQ-25 scores questionnaire
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.